CL King initiated coverage on Outset Medical
$OM
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
CL King initiated coverage of Outset Medical with a rating of Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/8/2024 | $6.00 → $3.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 6/21/2024 | $5.00 → $6.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 4/8/2024 | $6.00 | Buy | BTIG Research |
| 4/5/2024 | $6.00 | Neutral → Buy | CL King |
| 1/12/2024 | $14.00 → $6.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 10/13/2023 | $32.00 → $3.00 | Buy → Underperform | BofA Securities |
| 8/17/2023 | Neutral | CL King | |
| 11/11/2022 | $23.00 | Outperform | RBC Capital Mkts |
SAN JOSE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the first quarter 2025 after the close of trading on Wednesday, May 7, 2025. On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer, will host a conference call to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on
SAN JOSE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter, Year-End Highlights Net revenue of $29.5 million in the fourth quarter and $113.7 million in 2024 were both ahead of the company's prior guidance and preannouncement in January.Gross margin of 36.5% (37.7% on a non-GAAP basis) in the fourth quarter increased 220 basis points sequentially from the third quarter and 11 percentage points from the fourth quarter of 2023. Gross margi
SAN JOSE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full-year 2024 after the close of trading on Wednesday, February 19, 2025. On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer, will host a conference call to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 2:00 p.m. Pacific time (5:
SAN JOSE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the first quarter 2025 after the close of trading on Wednesday, May 7, 2025. On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer, will host a conference call to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on
SAN JOSE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset" or the "Company"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced a one-for-fifteen reverse stock split (the "Reverse Stock Split") of the Company's common stock, par value $0.001, which will become effective at 12:01 a.m. Eastern Time on Thursday, March 20, 2025. The Company's common stock will continue to trade under Outset's existing trading symbol, OM, on the Nasdaq Global Select Market ("Nasdaq") on a split-adjusted basis when the market opens on Thursday, March 20, 2025, with the new CUSIP number 6901452
SAN JOSE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will present at the 45th annual TD Cowen Health Care conference on Tuesday, March 4, 2025, at 2:30 p.m. Eastern time. A live and archived webcast of the presentation will be available on the "Investors" section of the Outset website at https://investors.outsetmedical.com/. About Outset Medical, Inc.Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo®
DEFA14A - Outset Medical, Inc. (0001484612) (Filer)
DEF 14A - Outset Medical, Inc. (0001484612) (Filer)
SCHEDULE 13G/A - Outset Medical, Inc. (0001484612) (Subject)
RBC Capital Mkts downgraded Outset Medical from Outperform to Sector Perform and set a new price target of $3.00 from $6.00 previously
RBC Capital Mkts upgraded Outset Medical from Sector Perform to Outperform and set a new price target of $6.00 from $5.00 previously
BTIG Research initiated coverage of Outset Medical with a rating of Buy and set a new price target of $6.00
SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)
SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)
SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)
Katie Szyman Appointed Chief Executive Officer and to Board of Directors Interim CEO Michelle Brennan Named Chairman of Masimo's Board Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer ("CEO") of the Company. Interim CEO Michelle Brennan has been appointed Chairman of Masimo's Board and Lead Independent Director Quentin Koffey has been appointed Vice Chairman. All of these changes are effective as of February 12, 2025. Ms. Szyman is currently worldwide president of Advanced Patient Monitoring at BD (Becton, Dickinson and Company). Previously, Ms. Szyman
Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company reducing the cost and complexity of dialysis, today announced the appointment of Dale E. Jones to its Board of Directors. "Dale brings more than 30 years of experience in building diverse and dynamic teams to Outset at a time of exceptional growth for our team," said Chair and CEO Leslie Trigg. "He leads with purpose and deeply understands the role values and culture play in building high-performance organizations, critical traits as we focus on transforming dialysis." Mr. Jones is a Senior Advisor at Diversified Search Group, and previously served as its CEO for more than eight years. He began his career in banking
Renowned MedTech leaders join EBR Board of Directors Highlights: Dr Evans, Dr Steinhaus and Ms Drexler to join EBR Systems' Board ahead of the planned A$110m IPO on the Australian Stock Exchange Board appointments follow the retirement of Mr Dave Stassen and Dr Leighton Read New EBR Systems' Board consists of Mr Allan Will, Mr John McCutcheon, Dr Christopher Nave, Mr Trevor Moody, Dr Bronwyn Evans, Dr David Steinhaus and Ms Karen Drexler EBR Systems, Inc., developer of the world's only wireless cardiac pacing system for heart failure, today announced the appointment of Dr Bronwyn Evans, Dr David Steinhaus and Ms Karen Drexler to the Board as Independent Non-Executive Directors. D
4 - Outset Medical, Inc. (0001484612) (Issuer)
4 - Outset Medical, Inc. (0001484612) (Issuer)
4 - Outset Medical, Inc. (0001484612) (Issuer)